Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Nearly three-quarters of patients with hard-to-treat blood cancers responded to a new dual-targeting CAR-T therapy, with some showing benefits lasting over a year.
A phase I/II study of bispecific CD19/20 CAR-T cells in 32 R/R B-NHL patients demonstrated a 74% overall response rate and 58% complete remission, with CAR-T persistence exceeding 500 days in long-term responders. Integrated spatial single-cell transcriptomics revealed tumor architecture subtypes linked to response durability, providing a spatially resolved framework for predicting CAR-T outcomes.
What the study was
- Study design
- Phase I/II clinical trial with spatial transcriptomic sub-study
- Population
- Adults with relapsed/refractory B-cell non-Hodgkin's lymphoma (primarily DLBCL)
- Sample size
- 32
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for Immunotherapy of Cancer
Why it surfaced
Phase I/II trial with strong efficacy signal (74% ORR, 58% CR) in high-unmet-need R/R B-NHL; bispecific targeting mitigates CD19 antigen escape; spatial transcriptomics adds novel predictive framework for patient selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.